This study aims to test the safety and effectiveness of daratumumab in combination with carfilzomib, lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma. The main outcome to be measured will be the presence of disease. This study is being conducted in New Jersey, and New York.
The details
Multiple myeloma is a cancer of the plasma cells in the blood. Treatment for multiple myeloma includes chemotherapy. Daratumumab(Darzalex) is a new drug used in the treatment of multiple myeloma that has not responded to a previous first treatment course. It has been approved for treatment in combination with lenalidomide (Revlimid) and dexamethasone.
This study aims to test the safety of daratumumab together with carfilzomib, lenalidomide, and dexamethasone, and whether it is effective. The main outcome to be measured is response to treatment.
Who are they looking for?
This study is recruiting 41 participants with newly diagnosed multiple myeloma. Participants should have adequate liver function. Participants should not be pregnant and be willing to be on birth control before starting treatment. Participants should not have severe kidney failure. Participants should not have uncontrolled high blood pressure or diabetes.
How will it work
All participants will receive a combination of daratumumab, carfilzomib, lenalidomide, and dexamethasone. They will be followed-up for 2 years, during which the presence of disease will be monitored.
